Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2019—Hematogenix announced the availability of the assessment of B-cell maturation antigen by flow cytometry and immunohistochemistry at its facilities in China, Asia, Europe, and the United States.
December 2019—nRichDX introduced its Revolution System, a high-yield sample prep platform designed to increase liquid biopsy–based test sensitivity by delivering more target input for molecular assays. The target yield increase is accomplished by combining the ability to process a range of sample volumes (3–50 mL) with recovery rates of 70–90 percent.
December 2019—The FDA granted breakthrough therapy designation to Novartis’ capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.
December 2019—Ortho Clinical Diagnostics, in collaboration with Thermo Fisher Scientific, has expanded the menu on MicroTip-capable Vitros systems to enable testing for fentanyl and tricyclic antidepressants.
December 2019—NeuMoDx Molecular announced an agreement with Amsterdam-based biotech company Self-screen BV to implement a CE-IVD-marked molecular diagnostic test for high-risk strains of human papillomavirus on the NeuMoDx 288 and NeuMoDx 96 molecular systems.
December 2019—Lucid Diagnostics received FDA 510(k) clearance for its EsoCheck Cell Collection Device. EsoCheck is a sterile, single-use disposable non-endoscopic balloon capsule catheter designed to collect and retrieve surface cells of the esophagus. The device is indicated for use in the general population of adults 22 years and older.
December 2019—Abbott announced that its Architect Stat High Sensitivity Troponin-I blood test has received clearance from the FDA for use on the Architect analyzer.
December 2019—Myriad Genetics announced the publication of results from a clinical outcomes study that demonstrated the Prolaris genetic test can identify men with low-risk prostate cancer who can safely select active surveillance and defer treatment.
December 2019—Beckman Coulter announced that its DxA 5000 total laboratory automation solution has received FDA 510(k) clearance and is available for sale in the United States.
December 2019—Qiagen announced the publication of a multicenter clinical study demonstrating the accuracy of its QIAstat-Dx syndromic testing solution for diagnosing the causes of acute gastroenteritis.
The study evaluated 385 patient samples at university hospital laboratories across Europe and showed the QIAstat-Dx Gastrointestinal Panel was highly sensitive (98.2 percent positive) and specific (99.9 percent negative). Multiple pathogens were identified in nearly one-third of the patient samples that tested positive. The study also cited the ability of the panel to provide cycle threshold values and amplification curves to aid in interpreting results.
